Dekkers Agrees to New Contract at Thermo Fisher, Amorese Joins NuGen as VP of R&D, Collins Wins Inamori Ethics Prize, and More | GenomeWeb
NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has agreed to a renegotiated contract with Marijn Dekkers that gives the CEO a base salary of $1.17 million per year as well as a target incentive bonus of 125 percent of base salary, the company disclosed in a filing this week with the US Securities and Exchange Commission. The new contract holds through the end of 2017.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.